Gilead 4Q Revenues: $5.8 billion (-2%) 4Q Earnings: $3 million (loss of $3.9 billion 4Q17) FY Revenues: $22.1 billion (-15%) FY Earnings: $5.5 billion (+18%) Comments: Total product sales in the quarter were $5.8 billion, flat compared to 4Q17. Sales were $4.5 billion in the U.S., $813 million in Europe and $398 million in other locations. HIV product sales were $4.1 billion in the quarter, up 21%. Growth was primarily due to the launch of Biktarvy in 2018 and the continued uptake of Descov...